Akt is stimulated by several growth factors, and mediates their cell survival signals. Recent studies have shown that Akt may play an intermediate role between phosphatidylinositol 3-kinase (PI3K) and p70 S6 kinase (p70S6K). Here we show that a novel nuclear p70S6K-related kinase (SRK) exists and that its in vivo function is also augmented by over-expression of Akt. Conceptual translation of the SRK cDNA revealed that the catalytic domain of SRK was highly homologous to that of p70S6K, and that the treatment of wortmannin or rapamycin strongly inhibited the phosphorylation and the activation of SRK, as in p70S6K. However, the Nand C-terminal domains of SRK were quite dierent from those of p70S6K. In immunolocalization analyses, we demonstrated a constitutive nuclear localization of SRK and the presence of a nuclear localization signal in its C-terminus. In vitro S6 phosphotransferase activities of SRK were stimulated with a slower kinetics by a variety of agonists to p70S6K. Interestingly, overexpression of the proto-oncogene Akt resulted in EGFindependent activation of SRK, while over-expression of kinase-dead Akt actually had an inhibitory eect. This relationship between Akt and SRK suggests that SRK may be a novel target of Akt and perhaps an important downstream component in the nuclear function of Akt.
Many reports support that the proto-oncogene Akt regulates various cellular metabolic pathways and also suppresses programmed cell death (Alessi and Cohen, 1998) . To exert these multiple roles, Akt phosphorylates a variety of cellular targets and regulates many cell signal transduction pathways either directly or indirectly. One of these pathways is the p70S6K cell signaling pathway. Over-expression of a membranelocalized form of Akt constitutively stimulates the enzymatic activities of p70S6K by unknown mechanisms (Burgering and Coer, 1995; Kohn et al., 1996) . p70S6K activation is a highly conserved mitogenic response, and the activities of p70S6K are stimulated by multiple serine/threonine phosphorylations by dierent upstream kinases. Recent studies have revealed some of the upstream regulators, which indicate at least two distinct signaling pathways in¯uence p70S6K. One pathway is regulated by PI3K and its downstream eectors, PDKs and Akt, as revealed by a variety of molecular biological and pharmacological analyses (Chung et al., 1994; Pullen et al., 1998) . A separate pathway contributing to p70S6K activation involves the FKBP12-rapamycin-associated protein (FRAP, also known as mTOR, RAFT, and RAPT) and was demonstrated using the immunosuppressant rapamycin (Chung et al., 1992) . How FRAP aects the p70S6K signaling pathway has not yet been fully understood, but recent results suggest the possibility that FRAP can regulate the p70S6K signaling pathway by its protein kinase activities, but not by a lipid kinase activity as its primary structure suggests (Burnett et al., 1998a) .
The requirement for p70S6K activity during the G1 phase was shown in experiments using neutralizing p70S6K antibodies that prevented both the activation of protein synthesis and the serum-induced entry of cells into S phase (Lane et al., 1993; Reinhard et al., 1994) . To elucidate the functional importance of p70S6K in cell growth regulation, other physiological targets besides S6 have also been sought. Indeed p85S6K, a splicing variant of p70S6K, phosphorylates cAMP-responsive element modulator (CREM) and stimulates its activities in a rapamycin sensitive manner (De Groot et al., 1994) . P85S6K, which contains a 23 amino acid extension at the Nterminus, is constitutively localized in the nucleus (Reinhard et al., 1994) .
In the present study, we have cloned the full length cDNA for a novel in vitro S6 kinase, S6 kinase-related kinase (SRK), from a human keratinocyte cDNA library, which has been also named as p70 S6 kinase b (Gout et al., 1998) or S6 kinase 2 (Shima et al., 1998) . As shown in Figure 1a , amino acid sequence comparisons revealed that SRK is closely related to the aII form of p70S6K. The catalytic domain of SRK is highly homologous (83.5% identity) to that of p70S6K. The activity of p70S6K depends on a complex pattern of phosphorylation catalyzed by three or more protein kinases that phosphorylate at least eight distinct serine/ threonine sites . All of these phosphorylation sites in p70S6K are conserved in SRK except for one in the autoinhibitory pseudosubstrate domain. However, the N-terminal (41.2% identity) and C-terminal (57.3% identity) regions of SRK are somewhat dierent from those of p70S6K aII (Figure 1a) . Especially, proline-and basic amino acidrich sequences in the C-terminus of SRK are very unique, which may be the cause of its dierent modes of regulation and functions in vivo. Additionally, the PDZ domain-binding site (Burnett et al., 1998b) in the extreme C-terminus of p70S6K is completely missing in SRK ( Figure 1a ). As shown in Figure 1b , a single SRK transcript (*1.8 kb) was detected in all of the tissues examined, except for the pancreas where two transcripts (*3.0 and 1.8 kb) were detected. SRK expression was quite low in the brain and the kidney, compared to the other tissues. A genomic Southern blot containing EcoRI-digested DNAs from various species was also examined with human SRK cDNA as a speci®c probe. The results shown in Figure 1c strongly support the presence of a single SRK gene in human as well as in some higher vertebrates.
To study the S6 kinase activity of SRK in response to various stimuli, HA epitope-tagged SRK was transiently expressed in Cos cells. Addition of various stimulants including serum, EGF, a phorbol ester, and cycloheximide led to the decreased electrophoretic mobility of SRK as determined by immunoblot analyses (not shown and middle panels of Figure 2b and c). This mobility shift coincided with the activities of SRK as measured by its ability of phosphorylate S6 protein in immune-complex kinase assays ( Figure 2) . Interestingly, the patterns of mobility shift and activation kinetics of SRK were quite dierent from those of p70S6K. Activated p70S6K usually showed multiple shifted bands according to their phosphorylation status (bottom panels of Figure 2b and c), but SRK consistently showed only two bands (middle panels of Figure 2b and c). This indicates that only a few selective sites from the conserved phosphorylation sites of SRK may be indeed phosphorylated by agonist stimulation in vivo. In addition, p70S6K was maximally activated at 30 min after stimulation (Chung et al., 1992) , but SRK needed about 2 h to be fully activated. Subcellular localization dierences and/or other activa- (A) + mRNA from the indicated human tissues was hybridized with a SRK cDNA fragment (nucleotides 280 ± 570) as described (Lee et al., 1998) . (c) A Southern blot containing 4 mg of EcoRI-digested genomic DNAs from dierent species was hybridized with the human SRK cDNA probe as described (Lee et al., 1998) Figure 2 (a) The S6 phosphotransferase activities of SRK. Cos cells transfected with pJ3H-SRK by the DEAE-dextran method (Chou and Blenis, 1996) were serum starved for 24 h, and then stimulated with 10% fetal bovine serum (SER), 25 ng/ml EGF (EGF), 100 ng/ml PMA (PMA), or 100 mM cycloheximide (CYH) for the time periods (min) as indicated. SRK was immunoprecipitated with 12CA5 anti-HA monoclonal antibody and the immune-complex S6 kinase activities of SRK were measured as described (Chung et al., 1992) . The results showed autoradiograms for P 32 -labeled S6 proteins from the experiments with dierent stimulations as indicated, which are representatives from at least three independent experiments. (b and c) Inhibition of the S6 phosphotransferase activities of SRK by rapamycin (b) and wortmannin (c). Cos cells transfected with pJ3H-SRK or -p70S6K aII were serum starved for 24 h and then stimulated with EGF (25 ng/ml), PMA (100 ng/ml), or cycloheximide (CYH, 100 mM) for 2 h in the presence (+) or absence (7) of rapamycin (Rap, 20 ng/ml) or wortmannin (Wort, 100 nM) pretreatment as described (Chung et al., 1992) . SRK was immunoprecipitated with anti-HA monoclonal antibody. The S6 kinase activities (top panels of b and c) of SRK were measured as described (Chung et al., 1992) . Anti-HA immunoblots for SRK (middle panels of b and c) and anti-p70S6K immunoblots (bottom panels of b and c) were prepared from the same lysates used for the kinase assays as described (Chung et al., 1992) . Arrows in panels of (b) and (c) indicate slow migrating species of SRK tion pathways speci®c to SRK may cause these dierences.
Rapamycin and wortmannin speci®cally block the phosphorylation and subsequent activation of p70S6K induced by various agonists as shown in p70S6K immunoblot analyses (bottom panels of Figure 2b and c) and as previously reported (Chung et al., 1992 (Chung et al., , 1994 . Similarly, the S6 kinase activities of SRK stimulated by EGF, PMA, and cycloheximide were strongly inhibited by rapamycin and wortmannin (top panels of Figure 2b and c) . Coincidentally, the generation of the slow migrating species of SRK by stimulation was also inhibited by rapamycin and wortmannin (middle panels of Figure 2b and c) . These results strongly suggest that SRK is phosphorylated and regulated by the PI3K-and the FRAPdependent cell signaling pathways.
To compare subcellular localization between SRK and p70S6K, we transiently transfected 293 cells with HA-tagged SRK or p70S6K aII isoform. Confocal immuno¯uorescence analyses clearly revealed a constitutive nuclear localization of SRK (Figure 3a) . Stimulation with EGF did not aect this localization (Figure 3a) . However, p70S6K aII, which had been dispersed throughout the cytoplasm, became concentrated in the inner plasma membrane (Figure 3a ). This pattern was maintained for at least 2 h more.
To further examine the nuclear localization mechanism of SRK, we investigated the involvement of a basic amino acid-rich stretch in the C-terminus of SRK, KKSK 474 RGR. 293 cells were transiently transfected with two dierent mutant forms of SRK, SRK474M (Lysine 474, a basic amino acid, was replaced by a neutral amino acid, methionine) or SRK474R (Lysine 474 was replaced by another basic amino acid, arginine). Confocal immuno¯uorescence analyses showed that SRK474M failed to localize in the nucleus (Figure 3a) . However, SRK474R, in which the basicity of residue 474 was conserved, maintained the nuclear localization pattern seen in the wild type (Figure 3a) . Stimulation with EGF did not aect the localization patterns of the mutants (Figure 3a) . These results unequivocally demonstrated that the unique basic amino-acid-rich region in the Cterminus of SRK is the sole cause for its nuclear localization. To examine whether subcellular localization of SRK aects its activity, we compared the S6 phosphotransferase activities of SRK474M and SRK474R. Interestingly, the activation kinetics or the strength of the activities of both SRK mutants was very similar to those of the wild type kinase (Figure 3b ). In addition, rapamycin and wortmannin strongly inhibited the activities of both mutants (Figure 3c ). These results suggest that the activation Figure 3 (a) Nuclear localization of SRK. 293 cells were transfected with 2 mg of pJ3H-wild type SRK (SRK), -p70S6K aII (p70S6K), -SRK474M (SRK474M) or -SRK474R (SRK474R) by LipofectAMINE method (GIBCO ± BRL Co.). Transfected cells were serum-starved for 24 h and stimulated with EGF (25 ng/ml) for 30 min, 2 h or untreated (control) as indicated. Cells were processed for immuno¯uorescence as described (Anderson et al., 1998) using 12CA5 monoclonal antibody as a primary antibody and FITC-conjugated goat anti-mouse antibody as a secondary antibody. (b) Change in localization has no eect on the activities of SRK. Cos cells were transfected with 1 mg of pJ3H-wild type SRK (WT), -SRK474M or -SRK474R by the DEAE-dextran method (Chou and Blenis, 1996) . Transfected cells were serum-starved for 24 h and stimulated with EGF (25 ng/ml) for 30 min, 2 h or untreated as indicated. SRK was immunoprecipitated with 12CA5 anti-HA monoclonal antibody. The S6 phosphotransferase activities of SRK (upper panel) were measured as described (Chung et al., 1992) . Anti-HA immunoblots for SRK (lower panel) were prepared from the same lysates used for the kinase assays. (c) The S6 phosphotransferase activities of the SRK mutants are inhibited by rapamycin and wortmannin. Cos cells were transfected with 1 mg of pJ3H-wild type SRK (WT), -SRK474M or -SRK474R by the DEAE-dextran method. Transfected cells were serum-starved for 24 h and then stimulated with EGF (25 ng/ml) for 2 h in the presence (+) or absence (7) of rapamycin (Rap, 20 ng/ml) or wortmannin (Wort, 100 nM) pretreatment as described (Chung et al., 1992) . SRK was immunoprecipitated with 12CA5 anti-HA monoclonal antibody. The S6 kinase activities (upper panel) of SRK were measured as described (Chung et al., 1992) . Anti-HA immunoblots for SRK (lower panel) were prepared from the same lysates used for the kinase assays mechanism of SRK is independent of its speci®c location within the cell.
Akt has been implicated in contributing to the activation of p70S6K (Burgering and Coer, 1995; Kohn et al., 1996) . Therefore, we examined if the Akt proto-oncogene product could also activate SRK. Coexpression of SRK with the wild type Akt or Gag-Akt constitutively stimulated the S6 phosphotransferase activity of SRK (Figure 4 ). In addition, overexpression of a kinase dead Akt partially suppressed the SRK phosphotransferase activity (Figure 4a ). This activation of SRK by Akt is sensitive to rapamycin and wortmannin (Figure 4) . These results strongly indicated that SRK is a novel nuclear target of Akt.
Since the inhibitors of p70S6K, namely rapamycin and wortmannin, can regulate SRK in the same manner, both SRK and p70S6K may share the same upstream regulatory elements, especially FRAP, PI3K, and probably PDKs. Despite these similarities between p70S6K and SRK, we could also ®nd several dierences, which will provide keys to understanding in vivo functions of the SRK signaling pathways. In the comparison of amino acid sequences of the two kinases, their N-and C-terminal domains show relatively lower sequence homologies, which implicates the important roles of these domains in determining the functional speci®city of SRK and p70S6K in vivo. The C-terminal domain of SRK has a proline rich region (residues 448 ± 456), and this structural difference may provide a basis for selective interactions between SRK and the SH3 domain-containing proteins. More interestingly, the last ®ve amino acid residues of p70S6K, which are required for binding to neurabin (a neural tissue-speci®c F-actin binding protein) are not conserved in SRK (Burnett et al., 1998b) . Such evidence suggests that structural differences in the N-and C-terminus of the kinases may contribute to determining the dierences in their in vivo functions.
In addition, we also showed that SRK has a nuclear localization signal, KKSK 474 RGR, in its C-terminal domain (Figure 3a ). During stimulation of the cell, SRK is permanently con®ned in the nucleus, and p70S6K becomes concentrated in the inner side of cytoplasmic membrane, as shown in Figure 3a . These results suggest that SRK may be a bona®de kinase for the known rapamycin-sensitive substrates including CREM and S6 protein present in the nucleus. The dierent localization of SRK and p70S6K also raises the question as to whether both kinases lie on the same signaling pathway. Since they are both sensitive to rapamycin and wortmannin, the simplest interpretation of the results is that a common kinase(s), which is present in both the nucleus and the cytosolic compartments, activates both of them. This view is partially supported by the fact that we observe no redistribution of SRK following EGF stimulation of quiescent cells. Also, recent reports revealed that Akt, a possible upstream regulator for both SRK (Figure 4 ) and p70S6K (Burgering and Coer, 1995; Kohn et al., 1996) , translocates from the plasma membrane to the nucleus after stimulation with mitogens, and phosphorylates nuclear as well as cytoplasmic targets (Andjelkovic et al., 1997) . However, we cannot exclude the possibility that there exist separate signaling pathways which regulate SRK and p70S6K. We have repeatedly observed the translocation of p70S6K aII from the cytosol to the plasmic membrane in response to EGF (see Figure 3a) , which strongly suggests the existence of a regulatory pathway(s) speci®c to p70S6K in the membrane. For example, members of Rho family Gproteins, Rac1 or Cdc42, bind p70S6K and induce its activation (Chou and Blenis, 1996) . The N-and/or Cterminal region of p70S6K may mediate its interaction with Rac1 or Cdc42, which allows its membrane translocation and subsequent activation.
Finally, we have also shown that the proto-oncogene Akt plays a dominant upstream regulatory role for SRK (Figure 4) . The results strongly suggest that SRK is one of the few characterized nuclear targets of Akt. To understand the functions of SRK in the cell, we are currently characterizing intermediates between Akt and SRK. Furthermore, characterizing how the PI3K-dependent and the rapamycin-sensitive signaling pathways selectively regulate the activities of SRK will lead to the discovery of novel cell signaling systems from the plasma membrane to the nuclear compartment. Transfected cells were serum-starved for 24 h and treated (+) with EGF (25 ng/ml), rapamycin (Rap, 20 ng/ml) or wortmannin (Wort, 100 nM) for 2 h or untreated (7) as indicated. SRK and Akt were immunoprecipitated with 9E10 anti-Myc monoclonal antibody or 12CA5 anti-HA monoclonal antibody, respectively. The S6 phosphotransferase activities of SRK (top panels of a and b) and the histone H2B kinase activities of Akt (lower middle panel of a) were measured as described (Burgering and Coer, 1995) . Anti-Myc immunoblots for SRK (upper middle panel of a and bottom panel of b) and anti-HA immunoblots for Akt (bottom panel of a) were prepared from the same lysates used for the kinase assays as described (Chung et al., 1992) 
